webinar register page

Webinar banner
MedTech - Disease Diagnostics and Digital Therapeutics
How far are we from achieving the health system world of the connected patient?

Oct 24, 2022 11:00 AM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

Flosonics Medical Inc.
Cala Inc.
Craig Eagle, MD
Chief Medical Officer @Guardant Health, Inc.
Dr. Craig Eagle currently serves as Guardant Health’s Chief Medical Officer. Prior to joining Guardant Health, Dr. Eagle has most recently served as Vice President of Medical Affairs Oncology for Genentech where he oversaw the medical programs across the oncology portfolio and developed innovative cancer trials and strategies in personalized health care. Prior to Genentech, Dr. Eagle has held several positions in the U.S. and internationally over his 19-year career at Pfizer including global head of the Oncology Medical and Outcomes Group. In this role, he oversaw the worldwide medical programs and development of numerous commercially successful drugs. Dr. Eagle currently serves on the Board of Directors for Generex Biotechnology and NuGenerex Immuno-Oncology.
HDMZ Inc. - Prospera
HDMZ Inc. - Signatera
Adam de la Zerda
Founder and CEO @Visby Medical, Inc.
Dr. Adam de la Zerda is the Founder and CEO of Visby Medical. Dr. de la Zerda is also a tenured Associate Professor at Stanford University School of Medicine. In 2012, he became the youngest faculty member at Stanford Medical School. He has experience in basic and translational research in molecular diagnostics, with biomedical engineering training during his PhD studies at Stanford University, chemistry and biochemistry postdoctoral training at University of California at Berkeley, and electrical engineering, computer science and physics training in his undergraduate studies at the Technion - Israel Institute of Technology. He has received over 20 honors and awards including Forbes Magazine 30-under-30 in Science and Healthcare in 2013 and 2014, Chan-Zuckerberg Investigatorship, DP5 Early Independence Award from the Director of the NIH, and gave a popular TED Talk (LINK).
Bela Denes, MD
Vice President, Global Medical Affairs @Lantheus
Bela S. Denes, M.D. is currently Vice President of Global Medical Affairs at Lantheus, responsible for overseeing the medical strategic plans, launch preparation and lifecycle management of PYLARIFY® (piflufolastat F18) and other legacy Lantheus products. Prior to joining Lantheus, he served as Global Medical Affairs Lead at Amgen and Vice President of Medical Affairs at Blue Earth Diagnostics until the company’s acquisition by Bracco Imaging in August 2019. Previously, he was with Genomic Health for more than five years as Senior Director of Medical Affairs for Urology and was the medical lead for the launch of the OncotypeDx GPS and ARV7 molecular assays in prostate cancer. Trained and educated at Washington University in St. Louis and certified by the American Board of Urology, he has more than 25 years of clinical and academic urology experience focusing on both benign and malignant men’s health issues.
Aseem Anand, PhD
Vice President, Digital Imaging Biomarkers @Lantheus
Aseem Anand, Ph.D. is the Vice President of Digital Imaging Biomarkers at Lantheus. Since 2018, Dr. Anand has been leading Sweden-based EXINI Diagnostics AB, a wholly owned subsidiary of Lantheus Holdings. Under his leadership, EXINI has developed and commercially launched the first FDA-cleared, AI-enabled software as a medical device to enhance the competitiveness of radiopharmaceutical assets. Prior to EXINI, Dr. Anand was managing the translational research and correlative clinical trials in the Department of Medicine at Memorial Sloan Kettering Cancer Center, NY, USA. He has more than 20 peer-reviewed publications and has presented high impact abstracts in several international conferences. Dr. Anand has received his Ph.D. in translational nuclear medicine from Lund University, Sweden and his master’s in biotechnology from Columbia University, New York, USA.